Annovis Bio CEO to Present Multi-Protein Alzheimer’s Research at Fierce Biotech Week 2026

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing buntanetap for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease, announced that President and CEO Maria Maccecchini, Ph.D., will present at Fierce Biotech Week 2026 in Boston on May 13, discussing the scientific basis for treating Alzheimer’s disease as a multi-protein disorder and highlighting Annovis’ approach of targeting multiple neurotoxic proteins simultaneously through its lead drug candidate, buntanetap, which is currently in a pivotal Phase 3 clinical trial. The presentation will focus on the company’s unique strategy of inhibiting the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. This approach is particularly significant because Alzheimer’s disease is increasingly recognized as a multi-protein disorder, and current therapies often target only a single protein, such as amyloid beta. Buntanetap’s ability to simultaneously inhibit multiple toxic proteins could potentially offer a more comprehensive treatment. The presentation at Fierce Biotech Week provides a platform for Annovis to share its scientific rationale and clinical progress with the broader biotech community. The company’s Phase 3 trial is evaluating buntanetap in patients with early Alzheimer’s disease, with topline data expected in the coming months. If successful, buntanetap could become a first-in-class therapy for Alzheimer’s and potentially other neurodegenerative diseases. For more information about Annovis Bio and its pipeline, visit the company’s website at www.annovisbio.com. Additional updates are available in the company’s newsroom at https://ibn.fm/ANVS. The full press release can be viewed at https://ibn.fm/kZ2Z4.